A carregar...
Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies
Zanubrutinib is a potent, second‐generation Bruton’s tyrosine kinase inhibitor that is currently being investigated in patients with B‐cell malignancies and recently received accelerated approval in the United States for treatment of relapsed/refractory mantle cell lymphoma. The objective of this an...
Na minha lista:
| Publicado no: | Clin Transl Sci |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7993273/ https://ncbi.nlm.nih.gov/pubmed/33306268 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12948 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|